Press Releases September 2, 2026 08:00 AM

CG Oncology to Present at Upcoming Investor Conferences in September

CG Oncology to Participate in September Healthcare Investor Conferences

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
CGON

CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on bladder cancer immunotherapies, announced the participation of its CEO, Arthur Kuan, in the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in September 2026. The company will webcast the presentations live and make replays available to investors.

CG Oncology to Present at Upcoming Investor Conferences in September
CGON
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CEO Arthur Kuan to present at two major healthcare investor conferences in September 2026.
  • Company focusing on developing and commercializing bladder-sparing therapeutics for bladder cancer patients.
  • Live webcasts of presentations available via CG Oncology's investor relations website.

DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

Cantor Fitzgerald Global Healthcare Conference
Presentation Time: Wednesday, September 9, 2026 at 8:00am ET

Morgan Stanley Global Healthcare Conference
Presentation Time: Monday, September 14, 2026 at 4:50pm ET

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com


Risks

  • Success of CG Oncology’s pipeline depends on clinical trial outcomes and regulatory approvals, which remain uncertain.
  • Market adoption of their bladder cancer immunotherapy is contingent on competitive landscape and medical community acceptance.
  • Investor response to conference presentations may be muted if no new data or significant updates are provided.

More from Press Releases

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment Sep 2, 2026 Sparklight Carrier Services Streamlines Wholesale Connectivity Ordering Sep 2, 2026 Trex Expands Outdoor Living Portfolio with Premium Lighting and Finishing Solutions Sep 2, 2026 ibex Expands Global Service Delivery Network with New State-of-the-Art Center in Egypt Sep 2, 2026 Greenland Mines Completes Acquisition of World-Class Rare Earth Nd-Pr Magnet and Defense Mine Asset Following Greenland Government Approval Sep 2, 2026